Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Autologous bone marrow infusion via portal vein combined with splenectomy for decompensated liver cirrhosis: A retrospective study
Bao-Chi Liu, Ming-Rong Cheng, Lin Lang, Lei Li, Yan-Hui Si, Ai-Jun Li, Qing Xu, Hui Zhang
Bao-Chi Liu, Lei Li, Yan-Hui Si, Department of Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
Bao-Chi Liu, Lin Lang, He Nuo Medical Clinic, Shanghai New Hongqiao International Medical Center, Shanghai 201100, China
Ming-Rong Cheng, Department of Anorectal Surgery, The Third Affiliated Hospital of Guizhou Medical University, Duyun 558000, Guizhou Province, China
Ai-Jun Li, Department of Hepatobiliary Surgery, Oriental Hepatobiliary Surgery Hospital, Shanghai 200433, China
Qing Xu, Department of Hepatobiliary Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
Hui Zhang, Department of Hepatobiliary Surgery, Shanghai Oriental Hospital Affiliated to Tongji University, Shanghai 200120, China
Author contributions: Liu BC outlined the content and reviewed the manuscript; Cheng MR reviewed the literature and wrote the manuscript; Lang L, Li L and Si YH performed this experimental work and analyzed the data; Li AJ, Xu Q and Zhang H participated in the experiments; Liu BC and Cheng MR contributed equally as joint first authors.
Supported by Shenkang Hospital Development Center of Shanghai, China, No. SHDC12016129.
Institutional review board statement: This study was approved by the Ethics Committee of the Shanghai Public Health Clinical Center (2013-030).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Bao-Chi Liu, Doctor, MD, Chief Physician, Department of Surgery, Shanghai Public Health Clinical Center, Fudan University, No. 2901 Caolang Road, Jinshan District, Shanghai 201508, China. liubaochi200227@aliyun.com
Received: April 6, 2023
Peer-review started: April 6, 2023
First decision: May 30, 2023
Revised: June 8, 2023
Accepted: July 11, 2023
Article in press: July 11, 2023
Published online: September 27, 2023
ARTICLE HIGHLIGHTS
Research background
Autologous bone marrow infusion (ABMI) was performed in patients with decompensated liver cirrhosis (DLC), with good results, but whether splenectomy affects outcome is still unclear.
Research motivation
The main purpose of this study was to determine the efficacy of ABMI combined with splenectomy in the treatment of DLC, to clarify the impact of splenectomy on liver and bone marrow function, and to provide a basis for routine splenectomy in patients with DLC.
Research objectives
To clarify the efficacy of ABMI combined with splenectomy in the treatment of DLC, and the impact of splenectomy on liver and bone marrow function, so as to provide basis for rational treatment of DLC.
Research methods
In this study, ABMI combined with splenectomy was used to treat DLC, and the impact of splenectomy on liver and bone marrow function was observed. These common clinical indicators (such as the prothrombin time, serum total bilirubin, ascites volume, white blood cell and platelets counts and so on.) were used to evaluate liver and bone marrow function, which were easy to be popularized in clinic.
Research results
This study shows that ABMI combined with splenectomy is effective in the treatment of DLC, which can help to recover liver and bone marrow function, and alleviate hypersplenism. However, the sample size of this study is small and the follow-up time is short, which needs to be further improved in future studies.
Research conclusions
ABMI combined with splenectomy is a new method for the treatment of DLC, which provides a theoretical basis for the treatment of other chronic diseases.
Research perspectives
Whether ABMI is suitable for other diseases such as osteoarthropathy, cerebral infarction sequelae, diabetes and other chronic diseases, they still need further study.
